MedTrace Logo

A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

NCT03003039 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2021-03-23

No results posted yet for this study

Summary

The purpose of this study is the area under the curve (AUC) for GB241 and rituximab concentrations.

Conditions

Interventions

BIOLOGICAL

GB241

Single intravenous infusion (IV) 375 mg/m2

BIOLOGICAL

Rituximab

Single intravenous infusion (IV) 375 mg/m2

Sponsors & Collaborators

  • Nanjing Yoko Biomedical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-05
Primary Completion
2019-05-20
Completion
2019-05-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03003039 on ClinicalTrials.gov